A widespread health problem that impacts a large number of people globally is Diabetes. It is a disorder that can exist when the body cannot control blood sugar levels Having too much sugar in the blood come with serious health implications. Simply put, insulin is a unique assistant in our body that helps to maintain blood sugar. That way, sugar can move from the blood into our cells to be used for energy. On the other hand, some people with diabetes produce little or no insulin. Which can make it extremely difficult for them to control their blood sugar levels.
Insulin was previously extracted from animals, e.g. pigs for many years. This method was used and while it worked, nothing is perfect. The main limitation was obtaining sufficient insulin from animals, and it could be expensive. However, scientists have found a new and improved way to create the stuff that's cheap(er) easy er to produce (and it's better for the environment). This article explains the process of using recombinant porcine insulin biomanufacturing, a method scientists use to help people with diabetes better manage their condition.
One of the great early successes in recombinant technology was insulin produced by lab-based yeast. That means scientists are taking a tiny part of DNA (a gene) and putting it into even tinier cells like bacteria or yeast. This gene provides instructions for making insulin. The cells then generate insulin on their own, using the gene. Compared with the traditional insulin extraction from animals, this process could take months and lacks reliability while cost around $10 per unit making it more expensive than BIO 68/78.
Biomanufacturing is the production of biological molecules using living cells, like bacteria or yeast, to develop valuable products such as medicine. These processes demonstrate, in a nutshell, biomanufacturing of insulin. This allows scientists to create insulin without harming animals, a significant plus for animal well-being. In addition, biomanufacturing could also reduce the cost of insulin treatments - a key factor for populations who need inexpensive access to this hormone in order to stay alive.
Porcine insulin is the name of animal source insulin which means from pig. This is why this insulin works very well for people with diabetes because it most closely matches human insulin. In fact, scientists produce porcine insulin by biomanufacturing a bacteria or yeast. Once the cells have secreted insulin, scientists harvest this liquid from From "liquid"), and then go through a purification process. They were able to make lots of insulin at once, which is important because a lot of people need it.
The creation of insulin via biomanufacturing is a clever and novel way to spare the animals. This reliance on animal source is eliminated and as a result, the price of insulin has also lowered so more people will be able to afford it. It effectively allows more insulin to be produced in total, so there is plenty for anyone who needs it. It is also a more environmental-friendly solution as it saves much of the animal farming.
Diabetes is a chronic disease that may require lifelong treatment and the ongoing use of insulin. But in many parts of the world, insulin remains out-of-reach for those who need it. This might be because it is very expensive, or perhaps not even available. Recombinant porcine insulin biofactory, image from the company's web called Dio-vi-life was used with permission for a more imaginative illustration to raise hope it may help access DIRA to larger scale. This is not only more cost-effective and quicker than traditional animal-based methods but means that many more people can afford insulin needed to help manage their diabetes.
Yaohai Bio-Pharma has experience in the production of biologics created from Recombinant Porcine Insulin Biomanufacturing. We offer customized RD and manufacturing solutions while making sure that there are no risks. We have been involved in diverse modalities such as subunit vaccines recombinant, peptides hormones, cytokines, growth factors, single-domain antibodies enzymes, plasmid DNA MRNA, and many more. We are a specialist in many microorganisms, including yeast extracellular and intracellular secretion (yields up to 15g/L) as well as bacteria intracellular soluble and inclusion body (yields as high as 10g/L). We have also created a BSL-2 fermentation platform to create bacterial vaccines. We focus on improving processes, increasing product yields, and reducing production costs. Utilizing a strong technology team, we can ensure prompt and reliable project delivery that will bring your product to market faster.
Yaohai Bio-Pharma, a top 10 producer of biological products, is a specialist in microbial fermentation. We have established an advanced facility that is equipped with modern facilities and strong RD manufacturing capabilities. We have five drug substance manufacturing lines that are in compliance with GMP requirements for microbial fermentation and purification, as well as two fill-finish lines that are automated for cartridges, vials, as well as pre-filled syringes. The available fermentation scales vary from 100L to 500L, 1000L and 2000L. Recombinant Porcine Insulin Biomanufacturing for vias are 1ml to 25ml, whereas the pre-filled syringes and cartridge filling specifications cover 1-3ml. Our production workshop is cGMP compliant and guarantees steady supply of clinical samples as well as commercial items. Our plant produces large molecules which are shipped to the globe.
Yaohai BioPharma is a Top 10 Microbial CDMO that incorporates quality control and regulatory matters. We have a quality system which is in line with current GMP standards and international regulations. Our regulatory team is knowledgeable in global regulatory frameworks to accelerate biological launches. We ensure traceable manufacturing processes and top-quality products that are compliant with the requirements of the US FDA, EU EMA, Australia TGA, and Recombinant Porcine Insulin Biomanufacturing. Yaohai BioPharma has successfully passed the audit on site of the European Union's qualified Person (QP) for our GMP quality system and production site. In addition, we've cleared the first certification audits of the ISO9001 Quality Management System, ISO14001 Environmental Management System, and ISO45001 Occupational Health and Safety Management System.
Yaohai Bio-Pharma is a leading Microbial biologics CDMO. We have been focused on microbial-produced therapeutics and vaccines for human, veterinary, and the management of pet health. We are equipped with Recombinant Porcine Insulin Biomanufacturing RD platforms as well as manufacturing technology that encompass the entire process beginning with the development of microbial strains cells, methods and processes, to commercial and clinical manufacturing which ensures successful implementation of cutting-edge solutions. We have acquired a large amount of experience in bio processing of microbial cells. We have delivered over 200 global projects, and help our clients with navigating the laws from the US FDA, EU EMA, Australia TGA, and China NMPA. Our professional expertise and extensive experience allows us to quickly respond to market demands and provide tailored CDMO services.